CDSCO Identifies Paracetamol and Other NSQ Drugs in Latest Report

Introduction of NSQ Drugs

The Central Drugs Standard Control Organisation (CDSCO) has recently identified over 50 drugs categorized as not of standard quality (NSQ). Within this list, Paracetamol tablets produced by various pharmaceutical companies, including Karnataka Antibiotics & Pharmaceuticals Ltd, have raised significant quality concerns.

CDSCO's Findings

According to the CDSCO's report, these NSQ alerts originate from regular monthly sampling by state drug officers. The reported medicines include a range of products:

• Paracetamol Tablets IP 500 mg - M/s. Karnataka Antibiotics and Pharmaceuticals Ltd.
• Amoxicillin And Potassium Clavulanate Tablets IP - M/s. Alkem Health Science
• Calcium And Vitamin D3 Tablets IP - M/s. Pure & Cure Healthcare Pvt. Ltd.
• Pantoprazole - M/s. Alkem Health Science
• Ibuprofen & Paracetamol Oral Suspension - M/s. Ornate Pharma Pvt. Ltd.

The comprehensive assessment highlighted that some manufacturers claimed these medicines were spurious, suggesting a need for further investigation. CDSCO's report emphasizes the critical nature of drug quality assurance in healthcare.

Response from Pharmaceutical Companies

Pharmaceutical firms like Hetero Drugs and Meg Lifesciences have denied responsibility for these findings, arguing that many of the drugs do not align with their production.

Implications for Patient Safety

This situation underscores the importance of regulatory vigilance. Patients should be aware and consult healthcare professionals regarding these developments and possible alternatives to affected medications.

Conclusion: Importance of Quality Control

With the increasing alert surrounding NSQ drugs, staying informed about FDA regulations and CDSCO updates is essential to ensure that the medications consumed meet safety and efficacy standards.